Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Editorial Commentary.
Prasad SM. Prasad SM. Urol Pract. 2022 Jul;9(4):303. doi: 10.1097/UPJ.0000000000000305.01. Epub 2022 May 12. Urol Pract. 2022. PMID: 37145784 No abstract available.
Editorial Comment.
Prasad SM, Kovac E. Prasad SM, et al. J Urol. 2023 Jul;210(1):105-106. doi: 10.1097/JU.0000000000003461.01. Epub 2023 Apr 27. J Urol. 2023. PMID: 37102721 No abstract available.
Editorial Commentary.
Prasad SM. Prasad SM. Urol Pract. 2023 Jan;10(1):87-88. doi: 10.1097/UPJ.0000000000000360.01. Epub 2022 Nov 3. Urol Pract. 2023. PMID: 37103451 No abstract available.
Editorial Comment.
Prasad SM. Prasad SM. Urol Pract. 2021 Mar;8(2):225. doi: 10.1097/UPJ.0000000000000200.02. Epub 2021 Jan 6. Urol Pract. 2021. PMID: 37145639 No abstract available.
Editorial Commentary.
Prasad SM. Prasad SM. Urol Pract. 2021 May;8(3):354. doi: 10.1097/UPJ.0000000000000214.02. Epub 2021 Mar 26. Urol Pract. 2021. PMID: 37145679 No abstract available.
Editorial Commentary.
Prasad SM. Prasad SM. Urol Pract. 2020 Nov;7(6):513-514. doi: 10.1097/UPJ.0000000000000130.01. Epub 2020 Sep 4. Urol Pract. 2020. PMID: 37287142 No abstract available.
Editorial Comment.
Fernandez G, Prasad SM. Fernandez G, et al. Among authors: prasad sm. Urol Pract. 2023 Nov;10(6):585-586. doi: 10.1097/UPJ.0000000000000448.01. Epub 2023 Sep 4. Urol Pract. 2023. PMID: 37856724 No abstract available.
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
Prasad SM, Huang WC, Shore ND, Hu B, Bjurlin M, Brown G, Genov P, Shishkov D, Khuskivadze A, Ganev T, Marchev D, Orlov I, Kopyltsov E, Zubarev V, Nosov A, Komlev D, Burger B, Raju S, Meads A, Schoenberg M. Prasad SM, et al. J Urol. 2023 Oct;210(4):619-629. doi: 10.1097/JU.0000000000003645. Epub 2023 Aug 7. J Urol. 2023. PMID: 37548555 Clinical Trial.
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
Autio KA, Higano CS, Nordquist L, Appleman LJ, Zhang T, Zhu XH, Babiker H, Vogelzang NJ, Prasad SM, Schweizer MT, Madan RA, Billotte S, Cavazos N, Bogg O, Li R, Chan K, Cho H, Kaneda M, Wang IM, Zheng J, Tang SY, Hollingsworth R, Kern KA, Petrylak DP. Autio KA, et al. Among authors: prasad sm. J Immunother Cancer. 2023 Mar;11(3):e005702. doi: 10.1136/jitc-2022-005702. J Immunother Cancer. 2023. PMID: 36948505 Free PMC article. Clinical Trial.
208 results